Credit Suisse Assumes Esperion Therapeutics (ESPR) at Outperform
Tweet
Share
E-mailGet Alerts ESPR Hot Sheet
Price: $2.13 +1.91%
Rating Summary:
9 Buy, 9 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
9 Buy, 9 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Credit Suisse analyst Judah C. Frommer assumes coverage on Esperion Therapeutics (NASDAQ: ESPR) with a Outperform rating and a price target of $45.00.
For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.
Shares of Esperion Therapeutics closed at $27.51 yesterday.
You May Also Be Interested In
- BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
- KeyBanc Starts Super Micro Computer (SMCI) at Sector Weight, 'shares currently trading relatively inline with its infrastructure peer group'
- Wells Fargo Reinstates Apache Corp. (APA) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
